Clinical Trial Update: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin [Phase 2]

View source ↗

Summary

Phase 2 study of pasireotide in rare neuroendocrine-origin tumors was terminated and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ectopic Acth Syndrome
• Nelson Syndrome
• Pancreatic Neoplasms
• Pituitary Neoplasms

Drugs mentioned

• Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Neoplasm, Pituitary Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2016-07-26